Raptiva RA trials halted
Executive Summary
Genentech and Xoma cease development of Raptiva in rheumatoid arthritis after Phase II trials fail to show "overall net benefit," companies say May 12. Raptiva (efalizumab, formerly Xanelim) BLA for once-weekly treatment of psoriasis was filed Dec. 23; the anti-CD11a monoclonal antibody is in Phase II for psoriatic arthritis...